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Abstract
Background: Migraine is a highly prevalent and disabling neurological disorder which is commonly linked with a
broad range of psychiatric comorbidities, especially among subjects with migraine with aura or chronic migraine.
Defining the exact nature of the association between migraine and psychiatric disorders and bringing out the
pathophysiological mechanisms underlying the comorbidity with psychiatric conditions are relevant issues in the
clinical practice.
Methods: A systematic review of the most relevant studies about migraine and psychiatric comorbidity was
performed using “PubMed”, “Scopus”, and “ScienceDirect” electronic databases from 1 January 1998 to 15 July 2018.
Overall, 178 studies met our inclusion criteria and were included in the current review.
Results: According to the most relevant findings of our overview, the associations with psychiatric comorbidities
are complex, with a bidirectional association of major depression and panic disorder with migraine. Importantly,
optimizing the pharmacological and non-pharmacological treatment of either migraine or its psychiatric comorbidities
might help clinicians to attenuate the burden of both these conditions.
Conclusions: The available data highlight the need for a comprehensive evaluation of psychiatric disorders in migraine
in order to promote an integrated model of care and carefully address the burden and psychosocial impairment
related to psychiatric comorbidities in migraine.
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Background
Both migraine and psychiatric disorders are prevalent
and burdensome conditions challenging the health care
systems worldwide [1–5]. These conditions show a large
overlap [6, 7] and epidemiological studies suggest that
patients with migraine – especially those with chronic
migraine (CM) and migraine with aura – are at in-
creased risk for major depression, anxiety, or suicidal be-
havior when compared to subjects without migraine
(e.g., [8–10]). Besides, according to a recent large
genome-wide association study, when compared to other
neurological disorders, migraine showed a higher genetic
correlation with psychiatric disorders suggesting com-
mon genetic bases or pathways [11]. The comorbidity
between migraine and psychiatric disorders is highly
relevant in the clinical practice, as it might influence
both the response to treatment and likelihood to achieve
remission [6]. Therefore, an interdisciplinary approach
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using pharmacological and non-pharmacological treat-
ment strategies aimed to manage both migraine and co-
morbid psychiatric disorder is essential.
The comorbidity between migraine and psychiatric
disorders presumably implies multiple causes, including
either unidirectional causal explanations, but even
shared environmental and/or genetic risk factors, and
their interaction at multiple levels [12]. All the men-
tioned aspects need to be carefully considered regarding
the diagnostic and therapeutic implications related to
migraine comorbidity.
This systematic review will provide an updated and
comprehensive overview of the current literature focusing
on the comorbidity of migraine with depression, bipolar
disorder (BD), anxiety disorders, post-traumatic stress dis-
order (PTSD), and other psychiatric disorders, including
personality, substance use, and somatoform disorders,
outlining the general findings, potential mechanisms of as-
sociation, and implications for migraine treatment.
Materials and methods
To achieve a high standard of reporting, we selected the
most relevant studies in accordance with the PRISMA
guidelines [13]. We included observational studies that ex-
plicitly and clearly report the adopted definitions of mi-
graine and its psychiatric comorbidities; we also included
clinical trials, open label studies, systematic reviews, guide-
lines, commentaries, editorials, and letters to editors focus-
ing on the review topic. When a title/abstract appeared to
describe a study eligible for inclusion, the full-text article
was carefully analyzed to evaluate its relevance for our sys-
tematic review. Eligible papers had to be written in English
and published from 1 January 1998 to 15 July 2018 on the
following 3 major electronic databases: PubMed, Scopus, or
ScienceDirect. The following search string was used in all
databases: (“Headache” OR “migraine”) AND “comorbidity”
AND (“psychiatric disorders” OR “substance abuse” OR
“personality disorders” OR “major affective disorders” OR
“bipolar disorder” OR “unipolar disorders” OR “psychotic
disorders” OR “psychoses” OR “suicid*” OR “anxiety” OR
“schizophrenia” OR “depression”). The reference lists of the
retrieved articles were also screened to find eligible studies
not covered by the above-mentioned search string. Two Re-
viewers (MP and GSf) conducted the literature search and
independently screened titles and abstracts; later, they re-
trieved and selected full-text articles. Disagreements among
these two Reviewers were solved by consensus. The rele-
vant steps and main results of the literature search are
shown in Fig. 1.
Major depression
Major depressive episodes are characterized by periods of
at least two weeks with symptoms including depressed or
irritable mood, decreased interest or pleasure in most
activities, significant weight change, change in sleep (in-
somnia or hypersomnia), change in activity (psychomotor
agitation or retardation), fatigue or loss of energy, guilt/
worthlessness, diminished ability to think or concentrate
or more indecisiveness, and suicidality [14].
Depression is almost twice as frequent in patients with
migraine when compared to the general population. The
prevalence estimates in migraine vary across countries,
from 6.1% to 73.7% (e.g., [15–17]) while the prevalence
odds ratios vary from 0.8 to 5.8 (see Table 1). Such
differences may be mainly due to different sex, age, and
ethnic composition of study samples, as well as from
different psychometric instruments aimed to assess mi-
graine and depression [18]. Comorbid major depression
is linked to more frequent and disabling headache [19].
Notably, the risk of suicide attempts is particularly
higher in migraine patients with comorbid anxiety and
depressive symptoms [20].
Mechanisms potentially involved in the comorbidity
Given the potential explanations of the comorbidity be-
tween migraine and major depression [12], studies indi-
cate the existence of a bidirectional relation [21]. For
instance, a cohort study found that the presence of each
disorder (both migraine or depression) enhanced the risk
for a first onset of the other [22], whereas in an older
sample the presence of depression did not predict the
onset of migraine [23]. Both migraine and depression
show a specific heritability of about 40–50% having a
polygenic background [24]. Twin studies suggest that
about 20% of the variability in both migraine and de-
pression can be attributed to shared genes with a bidir-
ectional pattern [25, 26].
The serotonin (5-HT) system plays a crucial role in the
association between migraine and depression. Indeed, pa-
tients with migraine have increased ictal 5-HT concentra-
tions and decreased interictal 5-HT plasma levels,
suggesting that a chronically reduced interictal 5-HT avail-
ability may predispose to cortical spreading depression
and increased sensitivity of trigemino-vascular pathways
[27]. Besides, a polymorphism in the 5-HT transporter
gene has been linked to migraine as well as depression
[28]. In addition, the migraine abortive drugs triptans
usually act as 5-HT agonists and even selective serotonin
reuptake inhibitors (SSRIs) may be used in preventing
migraine, even if they are not a first-line preventive treat-
ment and not recommended by existing guidelines.
A second possible key player in the association be-
tween migraine and depression is the dopaminergic sys-
tem, as a dopamine D2 receptor genotype is significantly
associated with comorbid migraine with aura, depres-
sion, and anxiety [29].
A study found significantly lower GABA cerebrospinal
fluid (CSF) levels in CM patients with depression when
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compared to those without, suggesting that GABA is a pos-
sible mediator of the association between CM and depres-
sion [30]. A further possible link between depression and
CM may be represented by the shared involvement of the
hypothalamic-pituitary adrenal (HPA) axis [31]. Specifically,
an imbalance between pro-inflammatory and anti-inflamma-
tory cytokines resulting in abnormal increased
pro-inflammatory cytokines levels has been hypothesized as
a possible link between depression, migraine, obesity, and the
progression from episodic migraine (EM) to CM, with
underlying dysfunctions in tryptophan metabolism and sero-
tonergic activation of the HPA axis [32]. This further points
towards the potential role of the 5-HT system in the associ-
ation between migraine and depression, suggesting multiple
neural mechanisms interacting in that association.
Recent neuroimaging studies showed that specific
pain-modulating brain areas, including the amygdala,
anterior cingulate cortex, and periaqueductal gray show
functional and structural alterations in both migraine and
affective disorders, suggesting a common matrix under-
lying these conditions [33]. This would imply a dysfunc-
tion of a “neuro-limbic” pain network underlying migraine,
in line with the findings from the current literature showing
that the presence of anxiety-depressive symptoms influence
the clinical presentation of migraine [34].
Finally, according to a psychological point of view,
specific shared vulnerabilities between migraine and de-
pression exist. Stress is a migraine trigger [35] and a risk
factor of migraine chronification [36], but it also has a
pivotal role in inducing major depression [33]. In
addition, broad and unspecific personality traits, mostly
neuroticism, have been implicated in the comorbidity
between depression and migraine [37].
Implications for treatment
The assumed bidirectional influence and the shared
mechanisms underlying migraine and major depression
could be used in a beneficial synergistic way when treat-
ing patients.
For instance, there is evidence that in patients with CM
and comorbid depression, the prophylactic use of onabo-
tulinumtoxin A significantly reduces headache as well as
depressive and anxiety symptoms [38, 39]. Similarly,
cognitive-behavioral therapy (CBT) improved headache
symptoms, depression, anxiety, and quality of life of pa-
tients with migraine and/or tension-type headache and
Fig. 1 Flowchart of study selection. Figure 1 includes all the relevant steps and main results of the literature search upon the main topic. The
most relevant studies have been selected in accordance with the PRISMA guidelines. Specifically, observational studies, clinical trials, open label
studies, systematic reviews, guidelines, commentaries, editorials, and letters to editors focusing on the review topic were included

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Dresler et al. The Journal of Headache and Pain           (2019) 20:51 Page 5 of 17
comorbid depression – with improvements that were
maintained for at least 4months [40]. Migraine guidelines
recommend the use of amitriptyline, a tricyclic antidepres-
sant, for migraine prophylaxis, which should be preferred
when a comorbid depression has been diagnosed [41, 42];
however, it should be noted that the amitriptyline doses
required for the treatment of migraine are lower than
those used to treat depression [42]. Conversely, caution is
needed regarding the use of flunarizine and beta-blockers
to prevent migraine as they may be contraindicated in the
presence of depression. Comorbid major depression is a
complex and more difficult to treat clinical condition; yet,
these patients do respond well to headache treatment, also
resulting in an improved quality of life [19]. Hence, treat-
ing both disorders adequately may result in symbiotic
treatment outcomes, preventing the development of
chronification [42].
Bipolar disorder
BD is characterized by a periodic course of depressive
episodes and episodes with exceptionally increased
mood (mania or hypomania). It is commonly divided
into BD type I (at least one manic or mixed episodes)
and BD type II (at least one hypomanic, but no full
manic phase), with BD I usually impairing more severely
the individual functioning [14].
Patients with BD display an increased prevalence of
migraine that can reach up to 55.3% (Table 1), although
– as stated above in the case of major depression – rates
may considerably vary across countries due to several
factors. Migraine prevalence seems to be higher in BD II
than BD I [43, 44], and mostly migraine precedes the
onset of BD [45]. In a population-based study, the preva-
lence of migraine was higher in subjects with both
manic and depressive episodes than in those with de-
pressive episodes only [46]. The available data suggest
that BD has a more severe course when it is comorbid
with migraine [47].
Mechanisms potentially involved in the comorbidity
BD shows the highest heritability in the group of affective
disorders, with a consistent overlap with migraine. The
available literature data show that a positive family history
of BD is a consistent risk factor for migraine [43, 47, 48],
pointing at towards a possibly shared hereditary basis.
Furthermore, based on a genome-wide linkage study [49]
and association study [50], some shared genetic vulner-
abilities may be supposed. Overall, multifactorial polygen-
etic mechanisms seem to confirm the existence of the
comorbidity between migraine and BD.
As already stated above for comorbid depression, sev-
eral neurotransmitter systems have been hypothesized to
be involved in BD and comorbid migraine, with studies
suggesting a dysfunction in serotonergic [27, 51, 52],
dopaminergic [53, 54], and glutamatergic pathways [55,
56]. Furthermore, rather at the cellular level, alterations
in specific sodium and calcium ion channels have been
found in both migraine [57–59] and BD [60–62], a find-
ing which might explain the common action of
anti-epileptic drugs such as valproate in both disorders
[63–65]. Finally, as in the case of major depression, even
for BDy pro-inflammatory cytokines might play a role in
determining the migraine-BD comorbidity [66].
Implications for treatment
Among the available treatments with documented stabil-
izing properties in BD, valproate and topiramate have
also been proven effective in the management of mi-
graine [65] and there is some evidence suggesting the ef-
fectiveness of lamotrigine (which is only approved for
the management of depressive recurrences in bipolar de-
pression) for migraine prevention ([63], but also see
[67]); the shared action of those drugs might point to a
similar pathophysiology underlying BD and migraine. In
addition to specific psychoactive medications, CBT [68]
and particularly social rhythm therapy – a variant of
interpersonal psychotherapy aimed at stabilizing en-
dogenous circardian rhythms – were effective for the
treatment of both BD and migraine [69, 70].
Conversely, the use of SSRIs and even more sero-
tonin–norepinephrine reuptake inhibitors (SNRIs) is as-
sociated with the risk of exacerbating mania or initiating
a more rapid cycling course in BD [71]. As migraine
usually precedes the BD diagnosis [44], a switch into
manic episodes might be precipitated by antidepressants
aimed to treat migraine or first symptoms of depression.
This underlines a considerable risk for misdiagnosis and
mistreatment in comorbid patients.
Anxiety disorders
Table 1 shows the quantitative data regarding the associ-
ation between migraine and anxiety. Notably, the preva-
lence of anxiety increases with migraine frequency [72,
73], suggesting a ‘dose-response’ effect; the comorbidity
between migraine and anxiety disorders is also enhanced
by the presence of medication overuse [74] and concur-
rent depression [75]. As for major depression, the risk of
suicide attempts is increased in patients with migraine
and anxiety disorders [20].
Panic disorder
Panic disorder (PD) is characterized by unexpected re-
current panic attacks, accompanied by physical symp-
toms such as sweating, trembling, palpitations, dizziness,
chest pain, the fear of going crazy or dying, often
co-occurring with agoraphobia [14]. When compared to
individuals without migraine, patients with migraine are
1.2 to 9.6 times more likely to be diagnosed with PD
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(e.g., [76]) (see Table 1). According to the current litera-
ture, PD occurs earlier in patients with migraine as com-
pared to those without [77]. However, the association
between the two conditions is likely to be bidirectional,
with the influence being primarily from headaches to PD
although a weaker, yet significant influence was observed
in the opposite direction [76]. The prevalence of PD is
about 2–3 times higher in CM than in EM [78].
Phobic disorders
Phobic disorders include specific phobia (fear of objects or
situations) and social phobia (fear of socially relevant in-
teractions) [14]. Evidence regarding the comorbidity be-
tween phobias and migraine is scarce [16, 79]. There
seems to be an overlap regarding specific avoidance be-
haviors in migraine and phobias, which led some re-
searchers to introduce the term ‘cephalalgiaphobia’, which
may be linked to the risk of transformation to CM and
medication-overuse headache (MOH) [80, 81]. A core fea-
ture of phobic-avoidant disorders is anticipatory anxiety,
which may be the reason why some patients take hold of
analgesics in the least warning of pain, eventually leading
to a vicious circle of headache and medication overuse.
Generalized anxiety disorder
Generalized anxiety disorder (GAD) is characterized by
the presence of pervasive anxiety and repetitive worries
about specific events [14]. The prevalence of GAD is
higher in subjects with migraine than in those without mi-
graine (see Table 1) [82]. If migraine is comorbid with de-
pression and anxiety, patients tend to suffer from more
severe migraine attacks, respond poorly to commonly
available treatments, and are at increased risk of develop-
ing MOH [82–86]. Besides, the presence of GAD seems
to precede migraine diagnosis which may have important
treatment implications [87].
Mechanisms potentially involved in the comorbidity
The bidirectional association between migraine and PD
suggests that shared genetic or environmental factors
might be involved in the comorbidity of PD with mi-
graine and other severe headaches [76, 85]. Migraine
and PD are likely to share an altered autonomic regula-
tion. A further possible mechanism of association is
somatization, which is typically found in patients with
PD and might increase the prevalence of somatic symp-
toms, including migraine headaches [84].
In a rat model of CM, researchers found a high preva-
lence of anxiety- and depression-like symptoms, which
could be reduced by a low-dose amitriptyline administra-
tion. Moreover, CM was associated with lower prefrontal
5-HT and dopamine levels. Translating these findings to
humans, alterations in these neurotransmitter systems
seem to contribute to both CM and anxiety [88].
Anxiety-depression symptoms in migraine may be
linked to higher migraine trigger susceptibility. Here,
central sensitization in migraine patients might be mod-
ulated and enhanced by comorbid anxiety-depression
symptoms, increasing the risk of transformation to CM
[89]. Such mechanism could be able to explain the
prevalence of more severe headache or CM in anxiety.
On the neural level, anxiety might directly influence
migraine symptoms acting on relay trigeminovascular
thalamic neurons transmitting headache-related noci-
ceptive signals, which are modulated by several excita-
tory and inhibiting input fibers. Surprisingly, the absence
of calcitonin gene-related peptide (CGRP)-containing fi-
bers around the thalamus indicates that CGRP is pre-
sumably not acting here, but more on a neurohormone
level [90]. Finally, a small Chinese study in MOH pa-
tients indicates that headache and anxiety may be linked
to changes in hippocampal volume [91].
Evidence regarding the comorbidity between migraine
and anxiety disorders is mainly focused on shared
neurotransmitter systems, primarily serotonergic dys-
function, which anxiety disorders share with depression.
Other potential mechanisms involve ovarian hormone
fluctuations, HPA axis dysregulation, and shared genetic
influences [92]. Migraine and anxiety have been associ-
ated with the serotonin transporter gene 5-HTTLPR
polymorphism and the C/C NcoI polymorphism within
the dopamine receptor D2 gene [29, 93, 94]. However,
there are association studies that did not find an associ-
ation between the migraine-PD comorbidity and dopa-
mine receptor genes [95]. This again points towards a
multifactorial pattern of association.
A Dutch twin study found that anxious depression
shared the heritability pattern of migraine, suggesting a
bidirectional causal relation [25], while another Dutch
study stressed the importance of anxiety and depression
in pain disorders and suggested that anxiety and depres-
sion explain a substantial amount of the migraine co-
morbidity with other pain conditions [92].
Interoceptive conditioning, fear of pain, anxiety sensi-
tivity, and avoidance behaviors have been considered as
vulnerability factors for migraine and PD in their devel-
opment and maintenance. Interactions between these
variables warrant further longitudinal studies to eluci-
date etiological trajectories and pathophysiological
mechanisms [94].
Implications for treatment
A retrospective study found that the treatment of PD
with antidepressant medications (SSRIs, tricyclic antide-
pressants [TCAs]) may may not only act beneficially on
PD but also on comorbid migraine [77]. This finding
hints towards a prophylactic effect, which could result in
a win-win-solution for the patients.
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Options for treating comorbid migraine and anxiety
disorders include anticonvulsants [67, 96]: pregabalin,
which is used for GAD, has been suggested as a useful
alternative prophylaxis in CM according to one
open-label study [97], while topiramate, which is used
for social phobia, has been suggested as a useful treat-
ment alternative for those who do not respond to or
cannot tolerate SSRIs [98]. The antiglutamatergic effect
of lamotrigine on migraine with aura and GABAergic ef-
fect of topiramate and valproate on migraine without
aura might act on the neural alterations implied in both
depression and anxiety [99].
Teaching about dysfunctional avoidance patterns in mi-
graine, including excessive painkiller intake, may help pa-
tients to get insights into their avoidance of migraine
triggers [100]. Henceforth, psychological interventions may
be important to prevent medication overuse. In addition,
treatment of phobias in CM may lead to lower anxiety and
depression levels as well as better quality of life [79].
Considering that anxiety increases the likelihood to de-
velop migraine, it is therapeutically important to notice
subthreshold symptoms. Associations between subthresh-
old anxiety and primary headache have been described
and subthreshold anxiety showed significantly higher ORs
for all headaches, migraine, and CM [101, 102].
The careful screening of children, adolescents, and young
adults who suffer from migraine for both anxiety and de-
pression, and vice versa, might result in better treatment
options and improved long-term outcomes for the patient
[103, 104]. Besides, the adequate screenings may reveal
underlying or subclinical psychiatric disorders [89].
An integration of behavioral strategies for managing co-
morbid conditions into existing treatment protocols pur-
sues to modify dysfunctional behaviors and cognitions [36].
Recognition of comorbid psychiatric disorders is also
advisable to prevent unwanted drug effects in comorbid
patients and to permit drugs effective for both disorders
[105], aiming to prevent headache worsening, chronifica-
tion, or medication overuse.
CBT strategies are usually aimed at modifying dysfunc-
tional behaviors, thoughts, and feelings that incidentally
maintain both depression and anxiety. This may enhance
adherence to pharmacotherapy, helping to minimize the
potential for headache chronification. Some behaviors
associated with anxiety include dysfunctional avoidance
patterns for which CBT may be really helpful in the clin-
ical practice [36, 106, 107].
A multidisciplinary treatment approach in migraine
(i.e., combining both pharmacological and psychological
approaches with other strategies such as physiotherapy)
(see e.g., [108]) should be aimed at excluding conflicts,
aggression as well as factors that contribute to anxiety.
The multidisciplinary treatment approach should be per-
sonalized and take into account both the patients’ usual
behavior and environment, thus helping patients to re-
cover their stability and avoid the anxious anticipation of
the next attack [109].
Stress and post-traumatic stress disorder
The relation between stress and migraine is bidirectional
and may be direct or indirect. Patients with migraine re-
port higher stress levels when compared to healthy con-
trols (e.g., [109]), and stressors are usually reported as
migraine triggers [84, 110–115]. Conversely, migraine it-
self acts as a stressor resulting in a vicious circle with a
strong impact on important individual domains such as
work and social functioning [116]. Stress exposure might
also mediate the association between migraine and other
psychiatric comorbidities, including major depression
[112], and is implied in the transformation of headache
into chronic headache [117, 118].
The development of PTSD mandatorily depends on
the direct or indirect exposure to traumatic life events
and is characterized by intrusive symptoms, avoidance,
and negative alterations in both cognitions and mood
[14]. PTSD is related to the development of pain disor-
ders [119], with a higher prevalence in patients with mi-
graine, and mostly CM, compared to healthy controls
[120]. Notably, the available studies found a higher inci-
dence of childhood abuse in migraine patients with BD
or depression as compared to those with migraine only
[110, 121]. There is also evidence suggesting that PTSD,
but not the mere exposure to a traumatic event, is corre-
lated with migraine [122], while in the absence of defin-
ite PTSD, only repetitive (≥3) traumatic events enhance
the risk for migraine [123–126]. Besides, CM is associ-
ated with a higher susceptibility for PTSD compared to
EM; indeed, patients with CM were more influenced by
traumatic events, as evident in more avoidant and
re-experiencing symptoms when compared to patients
with EM [127].
PTSD is more frequent among patients with CM
when compared to those with chronic tension-type
headache [128], suggesting that the association is specific
to migraine. Moreover, PTSD with comorbid depression
was associated with a higher risk of migraine chronifica-
tion when compared to depression alone [120]. In line
with those findings, an Italian study found that major
traumatic events were associated with CM and MOH
[129]. Not surprisingly, patients with migraine and co-
morbid PTSD report greater headache-related disability
and quality of life impairment than those with migraine
only [120, 122, 130].
Mechanisms potentially involved in the association
The higher prevalence of stress and stress-related disor-
ders in patients with migraine compared to
non-migraineurs might be explained by the central
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sensitization theory, which postulates a stress-induced ab-
normal activation of the trigeminal nucleus caudalis, hy-
pothesized to be involved in pain processing [131].
Stress-induced mechanisms acting on underlying genetic
and epigenetic vulnerability are able to modify neural cir-
cuits, neurotransmitter balance, and autonomic and endo-
crine responses [132]. The stress response seems to be
dysfunctional even in children with migraine [111, 133]. The
load of stress and repeated migraine attacks may impair the
allostasis of the brain, resulting in a dysregulated neural and
endocrine response, i.e., the “allostatic load” [134].
Serotonin is likely a mediator of the relation between
migraine and stress [27, 90], even if the available data
did not show a specific mediation of serotonin in the as-
sociation between PTSD and migraine. Stress plays a
major role even in the trigemino-vascular system, whose
activation is provoked from prolonged stress through
the action of the HPA axis [135].
A theory explaining the higher prevalence of migraine
in PTSD is the so-called “limbically augmented pain syn-
drome” [136]. According to that theory, if the normal
arousal induced by pain becomes chronic, the brain fails
to adjust adequately, causing an abnormal endocrine re-
sponse as well as permanent changes in the limbic system.
This phenomenon is shared by both migraine and PTSD,
in which the exposure to major traumatic events impairs
the normal limbic response. Another possible explanation
of the comorbidity between stress and migraine is that
chronic stress provokes a state of prolonged inflammation
leading to a damage and substantial modifications on
some sensitive specific brain areas, even implied in pain
perception [132, 136–139].
Implications for treatment
Individuating the presence of PTSD in patients with mi-
graine is crucial for the management of migraine, con-
sidering that treating PTSD alone could improve the
sense of well-being, and significantly reduce pain and
disability in patients with migraine [120].
Controlling the amount of stress may be crucial for
headache management [112] as migraine may also be
associated with a dysfunctional coping style [140].
Adolescents with CM are more prone to adopt pas-
sive coping strategies to face stress, especially when
migraine is associated with depression [141]. In this
context, CBT is increasingly gaining consensus as a
fundamental part of migraine management. CBT may
be really focused on attack prevention [106]. The aim
of this treatment approach is to change dysfunctional
behaviors which are significantly involved in maintain-
ing depression and anxiety [36] and comprises stress
management and coping [106]. The highest benefits
of CBT are observed when combined with pharmaco-
logical treatment [117, 142].
Other psychiatric comorbidities
Personality traits/disorders
Current evidence suggests that there are not dominant
personality profiles among migraine patients; however,
personality disorders seem to complicate headache treat-
ment [117, 143].
A meta-analysis of ten observational studies showed
that children with migraine tend to show more internal-
izing (“anxious, inhibited”) and externalizing (“aggressive
and antisocial”) behaviors, as measured by the Child Be-
havior Checklist (CBCL), than healthy children, even if
the difference was more evident for internalizing behav-
ior [144]. According to a systematic review, children
with migraine tend to show more somatic complaints
and internalizing behaviors than healthy controls, which
might be attributed to chronic pain rather than to psy-
chological dysfunctioning [145].
Compared to healthy controls, females aged 18–65 years
with a migraine had higher scores in the Harm Avoidance
(HA) and Persistence (P) sections and lower scores in the
Self-Directness sections of the Temperament and Character
Inventory [146]. A population-based study performed
among females aged 40–74 years found no association be-
tween lifetime migraine and personality traits or psychiatric
disorders; however, in elderly females (60–74 years), the risk
for active migraine was significantly and consistently associ-
ated with a history of major depression, higher levels of
stress susceptibility and somatic trait anxiety [147].
An Italian multi-center study performed in tertiary
headache clinics applied the Minnesota Multiphasic Per-
sonality Inventory (MMPI-2) and found – as compared
to healthy controls – that patients with MOH and epi-
sodic headache, respectively, scored higher in the
so-called ‘neurotic scales’ (i.e., Hypochondriasis, Depres-
sion, Hysteria) and lower in the Ego Strength and Dom-
inance scales; besides, patients with MOH had higher
scores in the Hypochondriasis and Health Concerns
scales when compared to those with episodic headache
[140]. Moreover, patients with CM and MOH did not
only report more stress, emotional and physical trau-
matic experiences than those with EM, but also show
more problems in identifying feelings according to an
alexithymia subscale [129]. These findings indicate that
CM, rather than EM, is associated with specific person-
ality traits. This does not mean that chronicity triggers
personality disorders; however, it is important that clini-
cians pay attention to personality traits in CM as they
may significantly interfere with the treatment.
Substance use behavior/disorders
Migraine and specific substance use may commonly
co-occur. For instance, early epidemiological research
found that nicotine dependence and illicit drug use was
more frequent among patients with migraine compared
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to those without; however, a review pointed out, that the
association may be more complex [117, 148]. More re-
cent data indicate that the association between migraine
and substance use was present only in patients with co-
morbid depression or PTSD [17, 149]. Thus, substance
use may be considered a consequence of other comorbid
psychiatric conditions [8].
Higher caffeine consumption could be a risk factor for
migraine transformation [150]; indeed, a population-based
study found that patients with chronic daily headache
were significantly more likely to have been higher caffeine
users compared to healthy control subjects [151]. Interest-
ingly, the HEAD-Hunt study found that higher caffeine
consumption was positively correlated with infrequent
headache and negatively correlated with frequent head-
ache [152], suggesting that either patients with frequent
headache avoid caffeine or high-caffeine consumption acts
exerting analgesic properties. So far, there is no unequivo-
cal conclusion.
Studies suggest that alcohol consumption is equally or
less prevalent in patients with migraine as compared to
the general population; possibly, patients self-restrict al-
cohol consumption because of its actual or assumed ac-
tion as a trigger of migraine attacks [23, 35, 153–155].
Yet, there is still uncertainty about the mechanisms by
which alcohol triggers migraine attacks [156].
Somatoform disorders/somatic symptoms disorder
Whether somatoform disorders are associated with migraine
is generally a matter of debate. According to a literature re-
view, patients with EM without other psychiatric comorbidi-
ties display a comparable prevalence of somatoform
disorders when compared to non-headache patients [117].
A cross-sectional study performed in a primary head-
ache center found that, among patients with CM, som-
atic symptoms were significantly more frequent than in
patients with EM, while during the follow-up a decrease
in somatic symptoms was highly associated with a de-
crease in headache frequency [157]. In line with these
results, the Primary Care Evaluation of Mental Disorders
(PRIME-MD) study found that, when compared to pa-
tients with episodic headaches, patients with CM had a
higher rate of somatic symptoms which increased, to-
gether with headache frequency, the likelihood to develop
a psychiatric comorbidity [158]. Finally, children with mi-
graine equivalents tend to have more somatic complaints
(see above, [145]) and feel more fearful and shy when
compared to those without migraine equivalents [159].
However, all those findings are related to somatic symp-
toms rather than to definite somatoform disorders.
Eating disorders
Whether eating disorders are linked to migraine is quite
controversial. A Finnish study found that, in women with
anorexia nervosa or bulimia nervosa, the prevalence of
migraine was almost 2-fold higher compared to women
without eating disorders (22% vs. 11%); however, a further
analysis revealed that the association between eating disor-
ders and migraine was mediated by depression [160].
Thus, eating disorders may enhance the likelihood to
develop migraine in specific subgroups of subjects, pos-
sibly through the influence of other factors such as anx-
iety or depression. If migraine patients present
themselves with low weight or rapid weight changes,
therapists should pay attention to depressive symptoms,
given the association between eating disorders and de-
pression. Moreover, specific manifestations of eating dis-
orders, such as dieting, fasting or skipping meals, are
often reported as migraine triggers [35, 155].
Discussion
Overall, our review underlines the consistent association
between migraine and psychiatric disorders (e.g., major
depression, bipolar disorder, anxiety disorders, PTSD, and
other mental disorders including substance-related behav-
ior and personality disorders) that might be attributed to
common etiological (both environmental or genetic) fac-
tors or to the existence of bidirectional relations between
the disorders, as for major depression and panic disorder.
Although the actual nature of this complex association be-
tween neurological and mental disorders is difficult to de-
termine given the available studies, for therapists it is
important to recognize it and to include it into the diag-
nostic and therapeutic process [161] (see Table 2). This
also requires a more intense collaboration between the
disciplines of neurology and psychiatry, which are mostly
taught separately in medical schools.
The present systematic review should be considered in
the light of the following limitations/shortcomings. For
instance, most studies included in the present review
used cross-sectional designs, limiting the assessment of
causal relations between phenomena (e.g., [161]). Be-
sides, the distribution of sex, age, and migraine subtype,
as well as methods to diagnose migraine and psychiatric
disorders were largely heterogeneous among the differ-
ent studies, limiting the possibility of quantifying the real
impact of comorbidities in the general population (for
more details, see Table 1). Moreover, there are few and
mostly indirect data examining the neural mechanisms
underlying the comorbidity between migraine and psy-
chiatric comorbidities. Having more than only one psy-
chiatric comorbidity (e.g., concurrent anxiety disorder
and major depression) poses another caveat which is
often not sufficiently considered in existing studies, but
may have further consequences on the course and treat-
ment of migraine [25, 120, 160]. All the mentioned criti-
cisms once again enhance the complexity of migraine
and psychiatric comorbidities regarding etiology,
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pathophysiology or interactions over time. However, the
more consistent implications from the reviewed studies
have been summarized in Table 2.
Major affective and anxiety disorders have been shown
to be the most frequent and disabling psychiatric comor-
bidities associated with migraine, influencing its clinical
course, treatment response, and clinical outcome. Here,
the comorbidity has important clinical and therapeutic
implications, demanding specific attention by practi-
tioners. For instance, having a comorbid major depression
or anxiety disorder can increase the likelihood of suicide
attempts in patients with migraine [20]. The comorbidity
with psychiatric disorders is not uniformly increased in
the different migraine subtypes, but generally more ele-
vated in patients with CM or migraine with aura, suggest-
ing the need for more specific care in those patients.
Genetic variants, dysfunction in neurotransmitters (es-
pecially 5-HT), and HPA axis dysregulation are among the
most supported pathophysiological mechanisms under-
lying the comorbidity between migraine and depression.
Specific neural network patterns overlap between both en-
tities, which may be the result of the above hypothesized
mechanisms. Unfortunately, no specific and valid bio-
markers have been documented for the risk of comorbid
migraine and depression. Still, it is not sufficiently clear, if
the observed biological or chemical parameters are indica-
tors of specific underlying etiological and pathogenic path-
ways or if they represent epiphenomena.
The relation between migraine and major depression is
likely to be bidirectional. Regarding the bipolar spectrum,
clinicians need to suspect and identify the possible comor-
bidity between migraine and BD, especially among female
patients and subjects with BD II. Here, the possible mis-
identification of unipolar depressive subtypes should be
avoided, as pharmacological indications for the two condi-
tions widely differ or may be counterproductive.
Whether the comorbidity between migraine and anxiety
is uni- or bidirectional is a matter of debate. Excess worry,
fear, and other anxiety symptoms such as avoidance be-
havior are usually part of the clinical migraine presenta-
tion, while, conversely, headache symptoms may also be
part of a clinical anxiety disorder. This implies the need to
correctly identify the clinical characteristics of both these
conditions, to derive a working hypothesis regarding
which of the disorders may be primary or secondary, as
the adequate treatment of the primary condition may be
beneficial for the outcome of the secondary condition. PD
appears to be more consistently associated with migraine
than most other anxiety disorders. Comorbid PD is associ-
ated with greater health care costs, higher disability, and
functional impairment as well as risk for chronification,
medication overuse, and henceforth MOH. As with mi-
graine and depression, the relation between PD and mi-
graine appears to be bidirectional. The link between
PTSD and migraine seems to be more evident in chronic
forms, as the repeated exposure to stressful situations/fac-
tors causes cortical response modification with modula-
tion of the vascular trigeminal system leading to a lower
pain threshold.
There are few and sometimes conflicting studies in
the current literature concerning the comorbidity be-
tween migraine and psychiatric disorders associated
with minor incidence in the general population, in-
cluding personality disorders, substance use disorders,
somatoform disorders, and eating disorders. Here, the
association may be also due to or mediated by con-
current major depression. Specific heed should be
paid to MOH, which is more common in patients
with comorbid psychiatric disorders [162]. In this
condition, pain-relieving drugs for the acute treatment
of headache symptoms may themselves lead to head-
ache when taken frequently for long periods. Here,
therapists should explain this phenomenon in detail
to the patients in order to assure a proper use of pre-
scribed or over-the-counter medication. In some cases
of MOH, comorbid psychiatric symptoms might be
considered an epiphenomenon of medication overuse
– at least animal data imply such a mechanism [163].
Reviewing the current literature, we are still far
from comprehensively understanding the biological
origin/axis underlying the migraine and psychiatric
disorder comorbidity. For most of the comorbid dis-
orders, the commonly mentioned pathogenic players
such as heritability, specific genes or neurotransmitter
systems may play a significant role (Fig. 2). As influ-
ences seem to be generally complex and dynamic in
their nature over time, simple therapeutic solutions
are not available and combined approaches are re-
quired. Instead, the involvement of different disci-
plines is needed in order to carefully account for
each patient’s disorder and treatment history in a
multimodal treatment approach perspective.
Clarifying the comorbidity between psychiatric disorders
and migraine is essential not only at the clinical diagnostic
level but above all for the complex therapeutic implica-
tions of such comorbidity [164]. CBT has been shown in
several population studies to be a valid alternative in
addition to pharmacological treatments in patients with
migraine and psychiatric comorbidity. Importantly, the
pharmacological prophylaxis of migraine might be influ-
enced by psychiatric comorbidities. Many biological and
neural aspects related to the comorbidity still need to be
clearly elucidated to better approach the real complexity
of this issue.
Conclusion
Our intention is to conclude this review emphasizing
three most relevant key points for clinicians:
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1) Psychiatric comorbidity in migraine is common and
invalidating.
2) The careful history taking and diagnostic
procedures related to migraine should carefully take
into account the existence of comorbidities.
3) Migraine management and treatment should be
tailored to consider the presence of psychiatric
comorbidities, taking into account the potential
beneficial or synergistic effects as well as treatment
complications.
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